Colorectal cancer with microsatellite instability and immunotherapies
Colorectal cancer with microsatellite instability and immunotherapies
Sebastian Stintzing (M.D.), Professor of Medicine, is Head of the Department of Hematology, Oncology and Cancer Immunology (CCM), Charité - Universitaetsmedizin Berlin. His research focuses on the treatment of GI cancer with a special focus on colorectal cancer. From 2012 to 2014, he was a research fellow at the Sharon Carpenter Laboratory at the University of Southern California Norris Comprehensive Cancer Center, Los Angeles, U.S.A. He coordinated the translational part and assisted the clinical study conduct of several studies and earned his Postdoctoral Lecture Qualification with a thesis on prognostic and predictive factors in the treatment of metastatic colorectal cancer. In 2012, he received the prestigious Research Fellowship Award from the German Cancer Aid in Germany. Prof. Stintzing is member of national and international cancer associations, member of the German S3 Guideline committee for colorectal cancer, and member of the steering committee of the working group Colorectal Carcinoma of the German AIO.
AMGEN, AstraZeneca, Bayer, BMS, CV6, Eisai, Isofol, Lilly, Merck KGaA, MSD, Pierre Fabre, Roche, Sanofi, Taiho, Takeda
Two emerging and two established targets
Announcing the publication of survey results
An expert overview of the EMERALD subgroup analysis
Managing patients with nccRCC: guidelines, recommendations, and best practice
Risk factors, diagnostic tools and treatment options for different patient groups
Exploring emerging treatment strategies presented at SABCS 2024